Re-188 lipiodol in hepatocellular carcinoma with portal vein thrombosis: a pilot study using novel chelating agent N-DEDC and its comparison with (A)HDD.
Shreya Shalimar Datta GuptaShamim A ShamimShivanand GamanagattiPriyanka GuptaMaroof A KhanMadhav B MalliaViju ChirayilAshutosh DashChandrasekhar BalPublished in: Nuclear medicine communications (2024)
Transarterial Re-188 lipiodol in HCC with PVT is safe and effective in disease control as well as improving survival outcome. Additionally, cost-effective and high-yielding novel agent N-DEDC appears to be a comparable alternative to (A)HDD for the same.